Allergan Lumigan, Alcon Travatan Studies Suggest Superiority To Xalatan
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Post-approval presentations for the two newest entrants to the glaucoma market, Allergan’s Lumigan (bimatoprost 0.03%) and Alcon’s Travatan (travoprost 0.004%), include studies suggesting potential superiority in IOP lowering to the market leader (Pharmacia’s Xalatan) and to the first-line agent timolol.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class